Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | SYK | P43405 | 1/20 | 0.63 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | FAM20C | Q8IXL6 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301779 | 0.84 | EGFR (0.78) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL17915952 | 0.84 | MAPT (0.82) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL307468 | 0.82 | AURKA (0.71) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL8348476 | 0.82 | IGF1R (0.60) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL270442 | 0.80 | MAPT (0.76) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL2174982 | 0.78 | RAB9A (0.53) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL653625 | 0.78 | SYK (1.00) | MAPTRAB9AMEN1KMT2ANPC1 | |
| Cardiogenol C SCHEMBL8286309 | 0.77 | ALDH1A1 (0.70) | MAPTRAB9AMEN1KMT2ANPC1 | |
| Cardiogenol C SCHEMBL29766906 | 0.77 | ALDH1A1 (0.70) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL270349 | 0.76 | RAB9A (0.69) | MAPTRAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | MAPT 4206/4885RAB9A 2095/4885MEN1 4175/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885RAB9A 2207/4885MEN1 4047/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885RAB9A 2207/4885MEN1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.